Last reviewed · How we verify
VBI-1901
At a glance
| Generic name | VBI-1901 |
|---|---|
| Sponsor | VBI Vaccines Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VBI-1901 CI brief — competitive landscape report
- VBI-1901 updates RSS · CI watch RSS
- VBI Vaccines Inc. portfolio CI